Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6826 AL 6840

Clinical drug research in chronic central neurodegenerative disorders

Müller T, Foley P.

Expert Rev Neurother. 2016 May;16(5):497-504. doi: 10.1586/14737175.2016.1163220. Epub 2016 Mar 21.

Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches

Salahuddin P, Fatima MT, Abdelhameed AS, Nusrat S, Khan RH.

Eur J Med Chem. 2016 May 23;114:41-58. doi: 10.1016/j.ejmech.2016.02.065. Epub 2016 Mar 2.

Omega-3 fatty acids for the treatment of dementia

Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A.

Cochrane Database Syst Rev. 2016 Apr 11;4(4):CD009002. doi: 10.1002/14651858.CD009002.pub3.

Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases

Hernando S, Gartziandia O, Herran E, Pedraz JL, Igartua M, Hernandez RM.

Nanomedicine (Lond). 2016 May;11(10):1267-85. doi: 10.2217/nnm-2016-0019. Epub 2016 Apr 14.

Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging

Vemuri P, Fields J, Peter J, Klöppel S.

Curr Opin Neurol. 2016 Aug;29(4):405-11. doi: 10.1097/WCO.0000000000000346.

A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease

McGhee DJ, Ritchie CW, Zajicek JP, Counsell CE.

BMC Neurol. 2016 Jun 16;16:92. doi: 10.1186/s12883-016-0606-3.

Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases

Parnetti L, Eusebi P, Lleó A.

Front Neurol Neurosci. 2016;39:117-23. doi: 10.1159/000445452. Epub 2016 Jul 26.

Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems

Cunha S, Amaral MH, Lobo JM, Silva AC.

Curr Med Chem. 2016;23(31):3618-3631. doi: 10.2174/0929867323666160824162401.

Endocannabinoid System in Neurological Disorders

Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM.

Recent Pat CNS Drug Discov. 2016;10(2):90-112. doi: 10.2174/1574889810999160719105433.

[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy]

Pupyshev AB, Korolenko TA, Tikhonova MA.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2016 Sep;66(5):515-540.

Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?

Jodeiri Farshbaf M, Ghaedi K.

Biometals. 2017 Feb;30(1):1-16. doi: 10.1007/s10534-016-9981-x. Epub 2016 Nov 16.

The rationale for deep brain stimulation in Alzheimer's disease

Mirzadeh Z, Bari A, Lozano AM.

J Neural Transm (Vienna). 2016 Jul;123(7):775-783. doi: 10.1007/s00702-015-1462-9. Epub 2015 Oct 6.

The use of pharmacological retromer chaperones in Alzheimer's disease and other endosomal-related disorders

Berman DE, Ringe D, Petsko GA, Small SA.

Neurotherapeutics. 2015 Jan;12(1):12-8. doi: 10.1007/s13311-014-0321-y.

Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis

Viola KL, Klein WL.

Acta Neuropathol. 2015 Feb;129(2):183-206. doi: 10.1007/s00401-015-1386-3. Epub 2015 Jan 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias